2 weeks Ago By ABMN Staff
Rhumbline Advisers grew its position in shares of Harvard Bioscience, Inc. ( NASDAQ:HBIO – Free Report ) by 24.9% in the second quarter, according to the company in its most recent 13F filing with the SEC.
The fund owned 47,753 shares of the medical instruments supplier’s stock after buying an additional 9,512 shares during the quarter. Rhumbline Advisers owned 0.11% of Harvard Bioscience worth $136,000 as of its most recent filing with the SEC.
Several other hedge funds also recently made changes to their positions in HBIO. Allspring Global Investments Holdings LLC acquired a new stake in Harvard Bioscience in the 2nd quarter valued at about $31,000. Riverwater Partners LLC raised its stake in Harvard Bioscience by 14.
1% in the 1st quarter. Riverwater Partners LLC now owns 93,197 shares of the medical instruments supplier’s stock valued at $395,000 after purchasing an additional 11,492 shares during the last quarter. Price T Rowe Associates Inc.
MD acquired a new stake in shares of Harvard Bioscience during the 1st quarter worth about $54,000. BNP Paribas Financial Markets raised its position in shares of Harvard Bioscience by 38.7% in the first quarter.
BNP Paribas Financial Markets now owns 75,970 shares of the medical instruments supplier’s stock valued at $322,000 after buying an additional 21,183 shares during the last quarter. Finally, Heartland Advisors Inc. boosted its position in Harvard Bioscience by 2.
6% during the first quarter. Heartland Advisors Inc. now owns 889,133 shares of the medical instruments supplier’s stock worth $3,770,000 after acquiring an additional 22,666 shares during the last quarter.
Institutional investors and hedge funds own 80.87% of the company’s stock. Harvard Bioscience Stock Performance NASDAQ:HBIO opened at $2.
72 on Monday. The company has a market cap of $118.13 million, a P/E ratio of -13.
60 and a beta of 1.30. The firm’s 50 day moving average is $2.
92 and its two-hundred day moving average is $3.31. Harvard Bioscience, Inc.
has a fifty-two week low of $2.50 and a fifty-two week high of $5.56.
The company has a quick ratio of 0.94, a current ratio of 2.05 and a debt-to-equity ratio of 0.
48. Harvard Bioscience Company Profile ( Free Report ) Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.
Further Reading Want to see what other hedge funds are holding HBIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Harvard Bioscience, Inc. ( NASDAQ:HBIO – Free Report ).
Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter ..
